Association of disease-modifying antirheumatic drug selection with hospitalised infection among youth with childhood-onset systemic lupus erythematosus

Jordan E. Roberts, Mary Beth F. Son(Boston Children's Hospital), Marshall Brown(Seattle Children's Hospital), Nidhi Naik(Icahn School of Medicine at Mount Sinai), Anna Faino, G. Alonzi(Boston Children's Hospital), Mersine A. Bryan(University of Washington), Joyce C. Chang(Boston Children's Hospital), Esi M. Morgan(Seattle Children's Hospital), Emily Zhang(Boston Children's Hospital), Cordelia Burn(Boston Children's Hospital), Jonathan D. Cogen(Northwestern University)
Lupus Science & Medicine
July 1, 2025
10.1136/lupus-2025-001607
Cited by 0

Related Papers

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
|New England Journal of Medicine|2020|2.7k
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
|JAMA|2021|852
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
|Arthritis & Rheumatology|2020|537
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2
|Arthritis & Rheumatology|2020|415